Clinical studies on chromium picolinate supplementation in diabetes mellitus - A review

Diabetes Technology and Therapeutics

Volumn 8, Issue 6, 2006, Pages 677-687

  Broadhurst, C Leigh ^a   Domenico, Philip ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CARBOHYDRATE; CHOLESTEROL; CHROMIUM; CHROMIUM CHLORIDE; CHROMIUM DERIVATIVE; CHROMIUM HISTIDINATE; CHROMIUM PICOLINATE; CHROMIUM POLYNICOTINATE; CORTICOSTEROID; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PLACEBO; PROTEIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BODY COMPOSITION; CHROMIUM; CLINICAL TRIALS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; INSULIN; IRON CHELATING AGENTS; LIPID METABOLISM; PICOLINIC ACIDS;

EID: 33845321762     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.8.677     Document Type: Review

References (85)

1. Centers for Disease Control and Prevention: The 2005 National Diabetes Fact Sheet. 2005. www.cdc.gov/diabetes (accessed July 2005).
2. American Diabetes Association: Diabetes Statistics-Total Prevalence of Diabetes & Pre-diabetes. 2005. http://www.diabetes.org/diabetes-statistics/ prevalence.jsp (accessed July 2005).
3. NIDDK: National Diabetes Statistics. NIH Publication Number 06-3892. 2005. http://diabetes.niddk.nih. gov/dm/pubs/statistics/index.htm (accessed July 2005).
4. World Health Organization: Diabetes Programme. 2006. http://www.who.int/ diabetes/facts/world_figures/en/ (accessed July 2005).
5. Evans GW: The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosocial Med Res 1989;11:163-180.
6. Anderson RA: Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998;17:548-555.
7. Vincent JB: The biochemistry of chromium. J Nutr 2000;130:715-718.
8. Anderson RA: Chromium, glucose tolerance, diabetes and lipid metabolism. J Adv Med 1995;8:37-50.
9. Cefalu WT, Hu FB: Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741-2751.
10. Wang H, Kruszewski A, Brautigan DL: Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 2005; 44:8167-8175.
11. Heimbach JT, Anderson RA: Chromium: recent studies regarding nutritional roles and safety. Nutr Today 2005;40:2-8.
12. Guallar E, Jimenez FJ, van 't Veer P, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM: Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 2005;162:157-164.
13. Rajpathak S, Rimm E B, Li T, Morris JS, Stampfer MJ, Willet WC, Hu FB: Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 2004;27:2211-2216.
14. Morris BW, MacNeil S, Hardisty CA, Heller S, Burgin C, Gray TA: Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 1999;13:57-61.
15. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786-1791.
16. Anderson RA, Kozlovsky AS: Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 1985;41:1177-1183.
17. Lukaski HC: Chromium as a supplement. Annu Rev Nutr 1999;19:279-302.
18. Anderson RA, Bryden NA, Polansky MM: Dietary chromium intake. Freely chosen diets, institutional diet, and individual foods. Biol Trace Elem Res 1992;32:117-121.
19. Campbell JD: Lifestyle, minerals and health. Med Hypotheses 2001;57:521-531.
20. Smart GA, Sherlock JC: Chromium in foods and the diet. Food Addit Contam 1985;2:139-147.
21. Kumpulainen J, Vuori E, Makinen S, Kara R: Dietary chromium intake of lactating Finnish mothers: effect on the Cr content of their breast milk. Br J Nutr 1980;44:257-263.
22. Juturu V, Komorowski JR: Consumption of selected food sources of chromium in the diets of American adults [abstract]. FASEB J 2003;17:A1129.
23. Offenbacher EG, Pi-Sunyer FX, Stoecker BJ: Chromium. In: O'Dell BL, Sunde RA, eds. Handbook of Nutritionally Essential Mineral Elements. New York: Marcel Dekker, 1997:389-411.
24. Kozlovsky AS, Moser PB, Reiser S, Anderson RA: Effects of diets high in simple sugars on urinary chromium losses. Metabolism 1986;35:515-518.
25. Gross LS, Li L, Ford ES, Liu S: Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004;79:774-779.
26. Davies S, Howard JM, Hunnisett A, Howard M: Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients - implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 1997;46:469-473.
27. Mertz W: The role of trace elements in the aging process. Prog Clin Biol Res 1990;326:229-240.
28. Anderson RA: Chromium metabolism and its role in disease processes in man. Clin Physiol Biochem 1986;4:31-41.
29. Anderson RA, Bryden NA, Patterson KY, Veillon C, Andon MB, Moser-Veillon PB: Breast milk chromium and its association with chromium intake, chromium excretion, and serum chromium. Am J Clin Nutr 1993;57:519-523.
30. Anderson RA, Sandre C, Bryden NA, Agay D, Chancerelle Y, Polansky MM, Roussel AM: Burn-induced alterations of chromium and the glucose/insulin system in rats. Burns 2005;32:46-51.
31. Campbell WW, Joseph LJ, Davey SL, Cyr-Campbell D, Anderson RA, Evans WJ: Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. J Appl Physiol 1999;86:29-39.
32. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC: Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002;132:1107-1114.
33. Ekmekcioglu C, Prohaska C, Pomazal K, Steffan I, Schernthaner G, Marktl W: Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes as compared to healthy controls. Biol Trace Elem Res 2001;79:205-219.
34. Aharoni A, Tesler B, Paltieli Y, Tal J, Dori Z, Sharf M: Hair chromium content of women with gestational diabetes compared with nondiabetic pregnant women. Am J Clin Nutr 1992;55:104-107.
35. Mita Y, Ishihara K, Fukuchi Y, Fukuya Y, Yasumoto K: Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate metabolism and renal function in type 2 diabetic mice. Biol Trace Elem Res 2005;105:229-248.
36. Anderson RA: Chromium in the prevention and control of diabetes. Diabetes Metab 2000;26:22-27.
37. Althuis MD, Jordan NE, Ludington EA, Wittes JT: Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 2002;76:148-155.
38. Guerrero-Romero F, Rodriguez-Moran M: Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Arch Med Res 2005;36:250-257.
39. Bahadori B, Wallner S, Hacker C, Boes U, Komorowski JR, Wascher TC: Effects of chromium picolinate on insulin levels and glucose control in obese patients with Type-II diabetes mellitus [abstract]. Diabetes 1999;48:A349.
40. Cheng N, Zhu X, Hongli S, Wo W, Chi J, Cheng J, Anderson R: Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. J Trace Elem Med Biol 1999;12:55-60.
41. Feng J, Lin D, Zheng A, Cheng N: Chromium picolinate reduces insulin requirement in people with type 2 diabetes mellitus [abstract]. Diabetes 2002;51:A469.
42. Ghosh D, Bhattacharya B, Mukherjee B, Manna B: Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 2002;13:690-697.
43. Kleefstra N, Houweling ST, Jansman FGA, Groenier KH, Gans ROB, Meyboom-de Jong B, Bakker SJL, Bilo HJG: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006;29:521-525.
44. Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449-1452.
45. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826-1832.
46. Morris BW, Kouta S, Robinson R, MacNeil S, Letters HS: Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet Med 2000;17:684-685.
47. Jovanovic-Peterson L, Gutierrez M, Peterson CM: Chromium supplementation for women with gestational diabetes mellitus. J Trace Elem Med Biol 1999;12:91-97.
48. Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habot B: Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004;74:178-182.
49. Ravina A, Slezak L, Mirsky N, Bryden NA, Anderson RA: Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 1999;16:164-167.
50. Ravina A, Slezak L, Rubal A, Mirsky N: Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. J Trace Elem Med Biol 1995;8:183-190.
51. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B: Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J 2005;149:632-636.
52. Cardoso CR, Salles GF, Deccache W: QTc interval prolongation is a predictor of future strokes in patients with type 2 diabetes mellitus. Stroke 2003;34:2187-2194.
53. U.S. Food and Drug Administration, Qualified Health Claims: Letter of Enforcement Discretion - Chromium Picolinate and Insulin Resistance. (Docket No. 2004Q-0144) 8-25-0005. http://www.cfsan.fda.gov/~dms/qhccr.html (accessed July 2005).
54. Cefalu WT, Bell-Farrow AD, Stegner J, Wand ZQ, King T, Morgan T, Terry JG: Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 1999;12:71-83.
55. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-Powell K, McElduff A: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005;28:712-713.
56. Komorowski JR, Juturu V: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance: response to Gunton et al. Diabetes Care 2005;28:1841-1842.
57. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
58. Kleefstra N, Bilo HJG, Bakker SJL, Houweling ST: [Chromium and insulin resistance]. Ned Tijdschr Geneeskd 2004;148:217-220.
59. Trow LG, Lewis J, Greenwood RH, Sampson MJ, Self KA, Crews HM, Fairweather-Tait SJ: Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. Int J Vitam Nutr Res 2000;70:14-18.
60. Thomas VL, Gropper SS: Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res 1996;55:297-305.
61. Abraham AS, Brooks BA, Eylath U: The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 1992;41:768-771.
62. Uusitupa MI, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivistoinen PE, Lehto JT: Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics. Am J Clin Nutr 1983;38:404-410.
63. Sherman L, Glennon JA, Brech WJ, Klomberg GH, Gordon ES: Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. Metabolism 1968;17:439-442.
64. Anderson RA, Polansky MM, Bryden NA, Canary JJ: Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr 1991;54:909-916.
65. Anderson RA, Polansky MM, Bryden NA: Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Biol Trace Elem Res 2004;101:211-218.
66. Anderson RA, Bryden NA, Polansky MM, Gautschi K: Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. J Trace Elem Exp Med 1996;9:11-25.
67. Anderson RA: Chromium and parenteral nutrition. Nutrition 1995;11:83-86.
68. DiSilvestro RA, Dy E: Comparison of acute absorption of various types of chromium supplement complexes. FASEB J 2005;19:A92-A93.
69. 51Cr picolinate in a rat model. Trace Elem Electrolytes 1994;11:182-186.
70. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278.
71. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group 52. JAMA 1999;281:2005-2012.
72. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
73. Newman HA, Leighton RF, Lanese RR, Freedland NA: Serum chromium and angiographically determined coronary artery disease. Clin Chem 1978;24:541-544.
74. Rabinowitz MB, Gonick HC, Levin SR, Davidson MB: Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes Care 1983;6:319-327.
75. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA: Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-174.
76. Dekker JM, Feskens EJ, Schouten EG, Klootwijk P, Pool J, Kromhout D: QTc duration is associated with levels of insulin and glucose intolerance. The Zutphen Elderly Study. Diabetes 1996;45:376-380.
77. Reaven GM: The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992;41:16-19.
78. American Association of Clinical Endocrinologists: Findings and Recommendations on the Insulin Resistance Syndrome. Washington, DC: American Association of Clinical Endocrinologists, 2002.
79. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13-26.
80. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25F-29F.
81. Reaven GM: Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88:2399-2403.
82. Vessby B: Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003;14:15-19.
83. Cases JA, Barzilai N: The regulation of body fat distribution and the modulation of insulin action. Int J Obes Relat Metab Disord 2000;24(Suppl):S63- S66.
84. Slabber M, Barnard HC, Kuyl JM, Dannhauser A, Schall R: Effects of a low-insulin-response, energy-restricted diet on weight loss and plasma insulin concentrations in hyperinsulinemic obese females. Am J Clin Nutr 1994;60:48-53.
85. Fuhr JP, He H, Goldfarb N, Nash DB: Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag 2005;8:265-275.